International Journal of Science and Research Archive
eISSN: 2582-8185
Cross Ref DOI: 10.30574/ijsra
Journal homepage: https://ijsra.net/

(REVIEW ARTICLE)

Check for updates

The biological basis of Parkinson's disease: A comprehensive review

Abderraouf Guessoum [1, 2, *], Mohammed Abouelsoud [1] and Ikram Khirani [3]

[1] *U: The Mind Company, Columbus, Ohio, United States.*
[2] *Public Hospital Institution Saadaoui El Mokhtar, Ain Oussera, Algeria.*
[3] *Public Hospital Institution Said Aouamri, Setif, Algeria.*

International Journal of Science and Research Archive, 2024, 12(02), 2685–2706

Publication history: Received on 01 July 2024; revised on 16 August 2024; accepted on 19 August 2024

Article DOI: https://doi.org/10.30574/ijsra.2024.12.2.1473

Abstract

Parkinson's disease (PD) is a complex neurodegenerative disorder characterized by motor and non-motor symptoms affecting millions of individuals worldwide. Despite extensive research efforts, the exact biological basis of PD remains elusive. This comprehensive review explores the current understanding of the pathophysiology of PD, focusing on epidemiology, genetics, environmental factors, molecular and cellular mechanisms, neuropathology, and clinical manifestations. The article synthesizes information from recent studies and expert opinions to provide a multifaceted perspective on the complex interplay of various factors contributing to PD development and progression. Key areas of discussion include the roles of alpha-synuclein aggregation, mitochondrial dysfunction, neuroinflammation, and the gut-brain axis. The review also highlights potential therapeutic targets and future research directions aimed at unraveling the intricate biological basis of PD.

Keywords: Parkinson's Disease; Neurodegeneration; Alpha-synuclein; Dopaminergic neurons; Neuroinflammation; Gut-brain axis

1. Introduction

Parkinson's disease (PD) is a debilitating neurodegenerative disorder that affects millions of individuals worldwide, with its incidence and prevalence increasing rapidly in recent years (Pringsheim et al., 2014). As the second most common neurodegenerative disorder after Alzheimer's disease, PD poses a significant burden on patients, caregivers, and healthcare systems globally (Dorsey et al., 2018). The characteristic motor symptoms of PD, including bradykinesia, rigidity, resting tremor, and postural instability, are often accompanied by a wide range of non-motor symptoms such as anosmia, constipation, depression, sleep disorders, and cognitive impairment (Chaudhuri et al., 2006). These symptoms arise from the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the accumulation of intracytoplasmic inclusions called Lewy bodies, which contain aggregated alpha-synuclein (Spillantini et al., 1997).

Despite the first description of PD by James Parkinson more than two centuries ago (Parkinson, 1817), the exact biological basis of this complex disorder remains incompletely understood. Over the years, extensive research efforts have shed light on the multifaceted nature of PD pathogenesis, implicating a complex interplay of genetic, environmental, and age-related factors in the development and progression of the disease (Kalia & Lang, 2015). The discovery of genetic mutations associated with familial forms of PD, such as those in the SNCA, LRRK2, PRKN, PINK1, and DJ-1 genes, has provided valuable insights into the molecular pathways involved in PD pathogenesis (Blauwendraat

* Corresponding author: Abderraouf Guessoum

et al., 2020). Furthermore, environmental exposures such as pesticides, heavy metals, and infections have been identified as potential risk factors for PD (Ascherio & Schwarzschild, 2016).

The role of the gut-brain axis and the microbiome in PD has also gained increasing attention, with evidence suggesting that gut dysbiosis and inflammation may contribute to the initiation and spread of alpha-synuclein pathology (Sampson et al., 2016).

This comprehensive review aims to provide a detailed and engaging exploration of the current understanding of the biological basis of PD. By synthesizing information from recent studies and expert opinions, the article will discuss the complex interplay of genetic, molecular, cellular, anatomical, and behavioral factors associated with PD development and progression. The review will also highlight potential therapeutic targets and future research directions, emphasizing the need for a multidisciplinary approach to unravel the intricate mechanisms underlying this devastating disorder.

2. Epidemiology

2.1. Global Prevalence and Incidence

Parkinson's disease is the fastest-growing neurological disorder, with projections estimating a staggering 12-17 million affected individuals worldwide by 2040 (Dorsey et al., 2018). The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 reported a global prevalence of

6.1 million PD cases, with a 2.4-fold increase in the number of affected individuals from 1990 to 2016 (GBD 2016 Neurology Collaborators, 2018). This rapid increase in PD prevalence can be attributed to factors such as population aging, improved diagnostic tools, and increased awareness of the disease (Dorsey et al., 2018).



Figure 1 Global Prevalence of Parkinson's disease Over Time

The incidence of PD also varies across different regions and populations. A systematic review and meta-analysis by Hirsch et al. (2016) estimated the global incidence of PD to be 18 per 100,000 person-years, with a higher incidence in men (21.6 per 100,000 person-years) compared to women (14.4 per 100,000 person-years). The incidence of PD increases with age, with the highest rates observed in individuals aged 70-79 years (Hirsch et al., 2016). Geographically, the incidence of PD is highest in North America, Europe, and Australia, and lowest in Asia and Africa (Hirsch et al., 2016).

2.2. Age, Gender, and Ethnic Distribution

PD primarily affects individuals in their later years of life, with the majority of cases occurring between the ages of 45 and 70 years (Dorsey et al., 2018). The risk of developing PD increases with age, with approximately 1% of the population over 60 years and 4% of those over 80 years being affected by the disease (Pringsheim et al., 2014). Age-

related changes in the brain, such as increased oxidative stress, mitochondrial dysfunction, and impaired protein degradation pathways, may contribute to the increased vulnerability to PD with advancing age (Reeve et al., 2014).

Gender differences in PD have been consistently reported, with men having a1.5 to 2-fold higher risk of developing the disease compared to women (Dorsey et al., 2018). This gender disparity may be attributed to a combination of genetic, hormonal, and environmental factors (Gillies et al., 2014). For example, the neuroprotective effects of estrogen have been proposed as a potential explanation for the lower incidence of PD in women (Gillies et al., 2014). Additionally, men may have higher occupational exposure to pesticides and other environmental toxins associated with an increased risk of PD (Gorell et al., 1998).

Ethnic differences in PD prevalence have also been observed, with the highest rates reported in individuals of Hispanic and non-Hispanic white ethnicity, followed by Asian and African American populations (Van Den Eeden et al., 2003). These differences may be attributed to a combination of genetic, environmental, and socioeconomic factors (Van Den Eeden et al., 2003). For example, variations in the frequency of PD-associated genetic mutations, such as LRRK2 G2019S, have been observed across different ethnic groups (Healy et al., 2008). Furthermore, differences in environmental exposures, access to healthcare, and cultural factors may contribute to the observed ethnic disparities in PD prevalence (Van Den Eeden et al., 2003).



Figure 2 Age-Specific Prevalence of Parkinson's Disease

2.3. Socioeconomic factors and Parkinson's disease

Studies have shown that socioeconomic factors such as education, income, and occupation are associated with the risk and progression of Parkinson's disease (PD) (Grandinetti et al., 1996; Shih et al., 2016). Specifically, lower levels of education and income have been linked to a higher prevalence of PD (Shih et al., 2016; Van Den Eeden et al., 2003). These associations may be influenced by factors including increased exposure to environmental toxins, limited access to healthcare, and reduced cognitive reserve (Shih et al., 2016; Van Den Eeden et al., 2003).

2.4. Occupational exposures and Parkinson's disease

Certain occupations, such as farming and agricultural work where individuals are exposed to pesticides like paraquat and rotenone, have been found to have a higher incidence of PD compared to the general population (Tanner et al., 2011; Priyadarshi et al., 2000). Other occupations associated with increased PD risk include welding, mechanics, and healthcare work, possibly due to exposure to heavy metals, solvents, and infectious agents (Tanner et al., 2011).

2.5. Economic burden of Parkinson's disease

Parkinson's disease imposes a substantial economic burden, with direct and indirect costs estimated at $51.9 billion in the United States in 2017 (Willis et al., 2019). As the prevalence of PD continues to rise, the economic impact is expected to grow, posing challenges to healthcare systems and society at large (Willis et al., 2019).

2.6. Anatomy and Physiology

Parkinson's disease (PD) is primarily characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc), a crucial component of the basal ganglia system. The basal ganglia, comprising structures such as the striatum (caudate nucleus and putamen), globus pallidus, subthalamic nucleus, and substantia nigra, play a pivotal role in regulating motor control, procedural learning, and other cognitive functions (Obeso et al., 2017).

The loss of dopaminergic neurons in the SNpc leads to a significant reduction in dopamine levels within the striatum, disrupting the normal functioning of the basal ganglia circuits. This disruption manifests in the hallmark motor symptoms of PD, including bradykinesia, rigidity, and resting tremor (Poewe et al., 2017).

In a healthy brain, the basal ganglia circuits modulate motor activity through direct and indirect pathways. The direct pathway facilitates movement by disinhibiting the thalamus, while the indirect pathway inhibits movement by increasing thalamic inhibition. Dopamine from the SNpc modulates these pathways by stimulating the direct pathway and inhibiting the indirect pathway, thus promoting smooth and coordinated movement (Cagnan et al., 2019).

In PD, the depletion of dopamine leads to an imbalance between these pathways. The reduced stimulation of the direct pathway and the increased activity of the indirect pathway result in excessive inhibition of the thalamus. Consequently, the motor cortex receives diminished excitatory input, leading to the characteristic motor deficits observed in PD patients (Galvan et al., 2021).

Recent research has revealed that the classical model of basal ganglia circuitry, while still valuable, represents a simplification of a more complex system. For instance, the discovery of the hyperdirect pathway, which provides a direct route from the cortex to the subthalamic nucleus, has added another layer of complexity to our understanding of motor control (Nambu et al., 2002). Furthermore, the role of the pedunculopontine nucleus in gait and balance control has gained increasing attention in PD research (Mena-Segovia et al., 2004).

Moreover, our understanding has shifted from viewing the basal ganglia purely in terms of firing rates to considering the importance of firing patterns and synchronization. Abnormal oscillatory activity, particularly in the beta frequency range (13-30 Hz), has been implicated in PD motor symptoms (Little and Brown, 2014). These oscillations are thought to disrupt normal information processing in the basal ganglia-thalamo-cortical circuits.

Additionally, recent studies have highlighted the heterogeneity of dopamine neurons and their projections, suggesting a more complex modulation of basal ganglia circuits than previously thought (Poulin et al., 2018). This nuanced view of dopaminergic function may help explain the varied motor and non-motor symptoms observed in PD.

These advancements in our understanding of basal ganglia circuitry not only provide a more comprehensive view of PD pathophysiology but also open up new avenues for therapeutic interventions, such as targeted deep brain stimulation protocols.

While dopamine is the primary neurotransmitter implicated in PD, other neurotransmitters also play significant roles in the disease's pathophysiology.

- Dopamine: The degeneration of dopaminergic neurons in the SNpc is the hallmark of PD. Dopamine is crucial for modulating motor function, and its deficiency leads to the classic motor symptoms of the disease (Poewe et al., 2017).
- Acetylcholine: In the striatum, cholinergic interneurons interact with dopaminergic neurons. The loss of dopamine results in an imbalance between dopamine and acetylcholine, contributing to motor symptoms. Anticholinergic drugs, which reduce acetylcholine activity, can help alleviate some PD symptoms (Schapira et al., 2017).
- Glutamate: Glutamatergic transmission is involved in the excitatory inputs to the basal ganglia. Alterations in glutamate levels and receptor activity have been observed in PD, affecting the balance of excitatory and inhibitory signals within the basal ganglia circuits (Calabresi et al., 2013).
- GABA: Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system. GABAergic neurons in the basal ganglia are crucial for the proper functioning of motor circuits. Dysregulation of GABAergic transmission in PD can contribute to the motor symptoms (Galvan & Wichmann, 2007).

- Serotonin: Serotonergic dysfunction is also evident in PD, particularly in non-motor symptoms such as depression and anxiety. The serotonergic system's involvement highlights the complex neurochemical changes occurring in PD beyond the dopaminergic system (Politis et al., 2010).

3. Cellular and Molecular Mechanisms in Parkinson's Disease

3.1. Alpha-Synuclein Aggregation:

Alpha-synuclein is a presynaptic neuronal protein implicated in the pathogenesis of Parkinson's disease (PD). In healthy neurons, alpha-synuclein is involved in synaptic vesicle regulation and neurotransmitter release.

However, in PD, alpha-synuclein undergoes misfolding and aggregation, forming insoluble fibrils that accumulate into Lewy bodies and Lewy neurites (Sulzer et al., 2017). These aggregates disrupt normal cellular function by impairing proteasomal and lysosomal degradation pathways, leading to neuronal toxicity and cell death (Wong & Krainc, 2017). The exact mechanism driving alpha-synuclein aggregation is not fully understood, but genetic mutations (e.g., SNCA) and environmental factors (e.g., pesticide exposure) are known to contribute (Stefanis, 2012).

3.2. Mitochondrial Dysfunction:

Mitochondrial dysfunction is a critical factor in PD pathogenesis. Mitochondria are essential for cellular energy production and regulation of apoptosis. In PD, mutations in genes such as PINK1, PARKIN, and DJ-1 impair mitochondrial function and dynamics, leading to decreased ATP production and increased susceptibility to cellular stress (Valdinocci et al., 2021). PINK1 and Parkin play a crucial role in mitophagy, the selective autophagic degradation of damaged mitochondria. Under normal conditions, PINK1 accumulates on the outer membrane of damaged mitochondria, recruiting Parkin, which ubiquitinates various mitochondrial surface proteins to promote their degradation by autophagosomes (Pickles et al., 2018).

Dysfunctional mitophagy due to mutations in PINK1 or Parkin results in the accumulation of damaged mitochondria, contributing to neuronal death (Zhang et al., 2019).

Mitochondrial dysfunction in PD also interacts with other pathogenic mechanisms, such as oxidative stress and alpha-synuclein aggregation. Impaired mitochondrial function leads to increased production of reactive oxygen species (ROS), exacerbating oxidative stress and causing further damage to cellular components (Zhou et al., 2022). Additionally, the oxidative environment can promote alpha-synuclein aggregation, linking mitochondrial dysfunction with proteinopathy in PD (Di Maio et al., 2018).

3.3. Oxidative Stress

Oxidative stress is a significant contributor to PD neurodegeneration. The brain, with its high oxygen consumption and abundant lipid content, is particularly vulnerable to oxidative damage. In PD, the imbalance between ROS production and antioxidant defenses leads to excessive oxidative stress.

3.3.1. Sources of ROS:

- Mitochondrial Dysfunction: Impaired function of mitochondrial complexes, particularly complex I, leads to increased ROS production (Zhou et al., 2022).
- Dopamine Metabolism: Dopamine auto-oxidation generates ROS and toxic quinones, contributing to oxidative stress (Segura-Aguilar et al., 2014).
- Environmental Toxins: Exposure to environmental toxins like pesticides (e.g., rotenone, paraquat) increases ROS production and has been linked to increased PD risk (Chin-Chan et al., 2015).

3.3.2. Antioxidant Defenses:

- Glutathione (GSH): A critical antioxidant in the brain, GSH levels are often depleted in PD, reducing the cell's ability to neutralize ROS (Jain et al., 2013).
- Superoxide Dismutase (SOD): This enzyme catalyzes the conversion of superoxide radicals to hydrogen peroxide, which is then reduced to water. Reduced SOD activity has been noted in PD (Zhang et al., 2021).

3.3.3. Cellular Targets of Oxidative Damage

- Proteins: Oxidation of alpha-synuclein can promote its aggregation, worsening its pathological effects (Emamzadeh, 2016).
- Lipids: Lipid peroxidation damages neuronal membranes, disrupting cellular integrity and function (Yoritaka et al., 1996).
- DNA: Oxidative damage to mitochondrial DNA impairs mitochondrial function, perpetuating the cycle of ROS production and cellular damage (Perier et al., 2020).

3.3.4. Vicious Cycle of Oxidative Stress

Oxidative stress, alpha-synuclein aggregation, and mitochondrial dysfunction form a self-perpetuating cycle. Mitochondrial dysfunction increases ROS production, which further damages mitochondria and other cellular components. Oxidative stress promotes alpha-synuclein aggregation, which in turn disrupts mitochondrial function, leading to more ROS production (Dias et al., 2013).

3.4. Therapeutic Implications

Understanding the role of oxidative stress in PD has led to potential therapeutic strategies aimed at enhancing antioxidant defenses and reducing ROS production. Approaches include the use of antioxidants (e.g., Coenzyme Q10, N-acetylcysteine) and gene therapies targeting mitochondrial function (Henchcliffe & Beal, 2008). More recent studies have explored novel antioxidant approaches, such as mitochondria-targeted antioxidants like MitoQ and SKQ1, which have shown promise in preclinical models (Fonseca et al., 2019). Additionally, the potential of Nrf2 activators in combating oxidative stress in PD has gained attention, with compounds like dimethyl fumarate showing neuroprotective effects in animal models (Cuadrado et al., 2018).

3.5. Emerging Research Directions

While oxidative stress remains a central theme in PD research, emerging areas of investigation are providing new insights and potential therapeutic targets. These include:

- The role of glial cells in oxidative stress: Recent studies suggest that astrocytes and microglia play crucial roles in modulating oxidative stress in PD, opening up new avenues for therapeutic intervention (Liddelow et al., 2017).
- Interplay between oxidative stress and neuroinflammation: Growing evidence points to a complex relationship between oxidative stress and inflammatory processes in PD, suggesting that combination therapies targeting both pathways may be more effective (Gelders et al., 2018).
- Precision medicine approaches: Given the heterogeneity of PD, there's increasing interest in developing personalized antioxidant strategies based on individual patient profiles and biomarkers of oxidative stress (Bloem et al., 2021).

These emerging areas of research highlight the complexity of oxidative stress in PD and underscore the need for multifaceted therapeutic approaches. As our understanding of these interconnected processes deepens, it may lead to more effective treatments for this challenging neurodegenerative disorder.

3.6. Neuroinflammation

Neuroinflammation is increasingly recognized as a key factor in PD. Microglia, the resident immune cells of the central nervous system, become activated in response to neuronal injury and alpha-synuclein aggregates. Activated microglia release pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, which exacerbate neuronal damage and promote further alpha-synuclein aggregation (Subhramanyam et al., 2019). Recent research has highlighted the complex roles of microglia in PD, with distinctions between

pro-inflammatory (M1) and anti-inflammatory (M2) phenotypes, suggesting a more nuanced involvement in disease progression (Subramaniam & Federoff, 2017).

Astrocytes, another type of glial cell, also play a crucial role in neuroinflammation. Reactive astrocytes can amplify inflammatory responses and contribute to neurotoxicity in PD (Liddelow et al., 2017). Chronic neuroinflammation leads to a sustained immune response, resulting in progressive neurodegeneration. Additionally, peripheral immune cells can infiltrate the brain and contribute to the inflammatory milieu, highlighting the systemic nature of PD-related inflammation (Harms et al., 2021).

Alpha-synuclein aggregates can activate microglia through various pathways, including toll-like receptors (TLRs) and NOD-like receptors (NLRs), triggering inflammatory cascades (Kouli et al., 2019). Moreover, emerging evidence suggests a significant role for the gut-brain axis in PD-related neuroinflammation, with gut microbiota dysbiosis potentially contributing to systemic inflammation and disease progression (Sampson et al., 2016).

3.7. The Gut-Brain Axis

The gut-brain axis has emerged as a crucial area of research in Parkinson's Disease, revealing a complex bidirectional communication system between the gastrointestinal tract and the central nervous system. This axis involves multiple pathways, including the vagus nerve, immune system, and enteric nervous system. Recent studies have shown that alpha-synuclein aggregates, a hallmark of PD, may originate in the enteric nervous system and propagate to the brain, supporting the "gut-to-brain" hypothesis of PD progression (Challis et al., 2020). PD patients often exhibit gut microbiome dysbiosis, which can contribute to intestinal inflammation, increased gut permeability, and systemic inflammation, potentially exacerbating neuroinflammation in the brain (Romano et al., 2021). The gut microbiome's role in producing neuroactive metabolites, such as short-chain fatty acids, and its involvement in neurotransmitter synthesis further underscores its importance in PD pathogenesis (Boertien et al., 2019). Gastrointestinal symptoms, often preceding motor symptoms in PD, provide additional evidence for the gut's involvement in the disease process (Heinzel et al., 2020). This evolving understanding of the gut-brain axis has opened up new therapeutic possibilities, including probiotic interventions, fecal microbiota transplantation, and dietary approaches aimed at modulating the gut microbiome (van Kessel and El Aidy, 2019). Ongoing research is focusing on identifying specific microbial signatures or metabolites as potential biomarkers for early PD diagnosis and exploring microbiome-based therapies for disease management (Lubomski et al., 2021). While the field shows great promise, further studies are needed to fully elucidate the complex interplay between the gut, the brain, and PD pathogenesis, and to translate these findings into effective clinical interventions.

4. Genetics

The genetics of Parkinson's disease is complex, involving multiple mutations and risk factors that contribute to its pathogenesis. Understanding these genetic components not only provides insights into the molecular mechanisms of PD but also opens avenues for the development of targeted therapies and personalized medicine approaches. Genetic studies have identified several key mutations and risk factors associated with PD, providing significant insights into the molecular mechanisms underlying the disease.

4.1. Known Genetic Mutations

- SNCA (Alpha-Synuclein) Gene: The SNCA gene, located on chromosome 4q22.1, encodes the protein alpha-synuclein. Mutations in SNCA, such as point mutations (e.g., A53T, E46K, A30P) and duplications/triplications of the gene, are associated with autosomal dominant PD (Puschmann, 2013). These mutations lead to increased aggregation of alpha-synuclein, forming Lewy bodies, a hallmark of PD pathology (Flagmeier et al., 2017).
- LRRK2 (Leucine-Rich Repeat Kinase 2) Gene: Mutations in the LRRK2 gene, located on chromosome 12q12, are the most common known cause of familial and sporadic PD. The G2019S mutation is the most prevalent, particularly among individuals of Ashkenazi Jewish and North African Berber descent (Healy et al., 2008). However, the frequency of this mutation varies significantly across different populations, being less common in East Asian populations (Tan et al., 2019). LRRK2 mutations lead to altered kinase activity and are associated with neuronal toxicity and degeneration through mechanisms involving mitochondrial dysfunction, autophagy impairment, and alpha-synuclein aggregation (Cookson, 2015).
- PARK Genes: Several other genes, collectively known as PARK genes, have been implicated in PD. These include:
- PARK2 (Parkin): Mutations in the PARK2 gene, located on chromosome 6q25.2-q27, cause autosomal recessive juvenile Parkinsonism. Parkin is an E3 ubiquitin ligase involved in proteasomal degradation of misfolded proteins and regulation of mitophagy (Kitada et al., 1998). Recent studies have further elucidated Parkin's role in mitochondrial quality control and its interactions with PINK1 (Pickrell & Youle, 2015).
- PINK1 (PTEN-Induced Kinase 1): Mutations in PINK1, located on chromosome 1p36, also cause autosomal recessive early-onset PD. PINK1 is crucial for mitochondrial quality control, working with Parkin to promote the degradation of damaged mitochondria through mitophagy (Valente et al., 2004). Current research highlights PINK1's role in initiating mitophagy and its potential as a therapeutic target (Pickrell & Youle, 2015).
- DJ-1: Mutations in DJ-1, located on chromosome 1p36, lead to autosomal recessive early-onset PD. DJ-1 functions as an oxidative stress sensor and protects cells from oxidative damage (Bonifati et al., 2003). Recent studies suggest DJ-1 also plays a role in mitochondrial function and protein quality control (Repici & Giorgini, 2019).

- ATP13A2: Mutations in ATP13A2, located on chromosome 1p36, are associated with Kufor-Rakeb syndrome, a rare form of autosomal recessive PD characterized by juvenile-onset and additional neurological symptoms. ATP13A2 encodes a lysosomal ATPase involved in metal ion transport and lysosomal function (Ramirez et al., 2006). New research indicates ATP13A2's involvement in α-synuclein metabolism and vesicular trafficking (van Veen et al., 2020).

4.2. Genetic Risk Factors

In addition to the above mutations, several genetic risk factors have been identified through genome-wide association studies (GWAS). These risk factors do not cause PD directly but increase susceptibility to the disease.

- GBA (Glucocerebrosidase) Gene: Mutations in the GBA gene, which encodes the lysosomal enzyme glucocerebrosidase, are the most common genetic risk factor for PD. Carriers of heterozygous GBA mutations have a significantly increased risk of developing PD. These mutations impair lysosomal function and lead to the accumulation of alpha-synuclein (Sidransky et al., 2009).
- Recent studies have further emphasized the importance of GBA mutations, which are now considered the most significant genetic risk factor for PD, present in about 5-10% of PD patients (Sidransky & Lopez, 2012).
- MAPT (Microtubule-Associated Protein Tau) Gene: Polymorphisms in the MAPT gene, located on chromosome 17q21.31, are associated with increased risk of PD. The H1 haplotype of MAPT is linked to PD and other neurodegenerative diseases, possibly due to its effects on microtubule stability and axonal transport (Zabetian et al., 2007). The relationship between MAPT variants and PD is complex and may involve interactions with other genetic and environmental factors (Robak et al., 2017).
- BST1 (Bone Marrow Stromal Cell Antigen 1) and Other GWAS Hits: GWAS have identified several loci associated with PD risk, including BST1, SNCA, LRRK2, and others. These loci highlight the polygenic nature of PD, where multiple genetic variants collectively contribute to disease susceptibility.
- Recent large-scale GWAS have identified over 90 independent risk variants for PD, further emphasizing the genetic complexity of the disease (Nalls et al., 2019).



Figure 3 Prevalence of Genetic Factors in Parkinson's Disease

4.3. Epigenetics and Gene-Environment Interactions

Emerging evidence suggests that epigenetic modifications, such as DNA methylation and histone acetylation, and gene-environment interactions also play crucial roles in PD. Environmental factors like pesticide exposure, head trauma, and lifestyle factors can influence genetic susceptibility to PD through epigenetic mechanisms (Marras et al., 2016). Recent studies have identified specific epigenetic changes associated with PD, such as alterations in DNA methylation patterns in PD-related genes (Chuang et al., 2017).

4.4. Environmental Factors in Parkinson's Disease

Environmental factors play a crucial role in the etiology of Parkinson's Disease (PD), often interacting with genetic susceptibilities to influence disease risk and progression. Recent research has shed light on various environmental exposures and lifestyle factors associated with PD:

- Pesticides and Herbicides: Exposure to certain pesticides and herbicides has been consistently linked to increased PD risk. Rotenone and paraquat, in particular, have been shown to induce parkinsonian symptoms in animal models and are associated with increased PD risk in epidemiological studies (Tanner et al., 2011). These compounds can disrupt mitochondrial function, increase oxidative stress, and promote α-synuclein aggregation (Nandipati & Litvan, 2016). A meta-analysis by Yan et al. (2018) found that overall pesticide exposure was associated with a 1.62-fold increase in PD risk.
- Heavy Metals: Occupational exposure to heavy metals, particularly manganese, lead, and iron, has been associated with increased PD risk. These metals can accumulate in the brain, particularly in the basal ganglia, leading to oxidative stress and neuroinflammation (Bjorklund et al., 2018). A recent study by Lucchini et al. (2021) found that even low-level environmental exposure to manganese was associated with altered dopaminergic function and increased risk of parkinsonian symptoms.
- Air Pollution: Emerging evidence suggests that long-term exposure to air pollution, particularly fine particulate matter (PM2.5) and nitrogen dioxide (NO2), may increase PD risk. A large-scale study by Liu et al. (2016) found that individuals exposed to high levels of NO2 had a 40% increased risk of developing PD. The mechanisms may involve neuroinflammation, oxidative stress, and blood-brain barrier disruption (Chen et al., 2017).
- Traumatic Brain Injury (TBI): A history of TBI has been associated with increased PD risk. A recent meta-analysis by Gardner et al. (2018) found that individuals with a history of TBI had a 57% higher risk of developing PD. The link may be due to chronic neuroinflammation, disruption of the blood-brain barrier, and acceleration of α-synuclein aggregation following TBI (Jafari et al., 2020).
- Occupational Exposures: Certain occupations involving exposure to solvents, metals, and electromagnetic fields have been associated with increased PD risk. A comprehensive review by Gunnarsson & Bodin (2019) found elevated PD risk in occupations such as farming, welding, and teaching. The mechanisms likely involve a combination of chemical exposures and other job-related factors.
- Lifestyle Factors: Several lifestyle factors have been associated with altered PD risk:
    - Diet: A Mediterranean-style diet rich in fruits, vegetables, whole grains, and omega-3 fatty acids has been associated with reduced PD risk (Metcalfe-Roach et al., 2021). Conversely, high consumption of dairy products has been linked to increased risk (Hughes et al., 2017).
    - Physical Activity: Regular exercise has been consistently associated with reduced PD risk and slower disease progression. A meta-analysis by Fang et al. (2018) found that individuals with high levels of physical activity had a 29% lower risk of developing PD.
    - Smoking and Caffeine: Paradoxically, smoking and caffeine consumption have been associated with reduced PD risk. A meta-analysis by Li et al. (2015) found that current smokers had a 40% lower risk of PD compared to never-smokers. Similarly, coffee consumption has been associated with a
    - dose-dependent reduction in PD risk (Noyce et al., 2012). However, given the numerous health risks ssociated with smoking, it is not recommended as a preventive measure.
- Gut Microbiome: Recent research has highlighted the potential role of the gut microbiome in PD pathogenesis. Alterations in gut microbial composition have been observed in PD patients, potentially contributing to α-synuclein aggregation and neuroinflammation (Keshavarzian et al., 2015). Environmental factors such as diet, antibiotics, and toxin exposure can influence the gut microbiome, potentially modulating PD risk (Sampson et al., 2016).
- Viral Infections: There is growing interest in the potential role of viral infections in PD etiology. The COVID-19 pandemic has reignited this discussion, with some studies suggesting a potential link between SARS-CoV-2 infection and increased risk of parkinsonism (Beauchamp et al., 2020). However, more research is needed to establish causal relationships between specific viral infections and PD.



Figure 4 Environmental Risk Factors for Parkinson's Disease

5. Progression of Parkinson's Disease:

The progression of PD is heterogeneous, with significant variability in the rate and pattern of symptom development among individuals (Fereshtehnejad et al., 2019).

5.1. Stages of Parkinson's Disease:

5.1.1. Prodromal Stage:

The prodromal stage of Parkinson's Disease (PD) represents a pre-motor phase that can precede clinical diagnosis by years or even decades. This stage is characterized by subtle, non-motor symptoms that are increasingly recognized as early indicators of PD. Key features of the prodromal stage include REM sleep behavior disorder (RBD), olfactory dysfunction, constipation, depression, anxiety, and subtle cognitive changes. Recent research by Heinzel et al. (2019) has demonstrated that combinations of these prodromal markers can predict PD risk with high accuracy, potentially allowing for earlier intervention and management strategies.

5.1.2. Early Stage (Hoehn and Yahr Stages 1-2):

The early stage of PD is marked by the onset of characteristic motor symptoms, typically presenting unilaterally. Patients may experience tremor at rest, rigidity, bradykinesia, and mild postural instability. At this stage, most patients maintain independence in daily activities despite these symptoms.

Neuroimaging studies have shown that by the time motor symptoms become apparent, there is already a significant loss of dopaminergic neurons in the substantia nigra, estimated at 50-60% (Kordower et al., 2013). This underscores the importance of identifying PD in its prodromal stage for potential neuroprotective interventions.

5.1.3. Moderate Stage (Hoehn and Yahr Stage 3):

As PD progresses to the moderate stage, motor symptoms become bilateral and more pronounced. Patients begin to experience more significant balance problems and falls, freezing of gait, and speech difficulties. Non-motor symptoms also become more prominent, including cognitive impairment and autonomic dysfunction such as orthostatic hypotension and urinary difficulties. It's at this stage that many patients begin to experience complications related to long-term levodopa therapy, including motor fluctuations and dyskinesias (Olanow et al., 2020). These treatment-related complications add another layer of complexity to patient management.

5.1.4. Advanced Stage (Hoehn and Yahr Stages 4-5):

In the advanced stage of PD, both motor and non-motor symptoms become severe and debilitating. Motor symptoms include frequent falls, inability to stand or walk unassisted, severe motor fluctuations and dyskinesias, and speech that

may become unintelligible. Cognitive decline often progresses, potentially leading to dementia. Non-motor symptoms, particularly autonomic dysfunction, often dominate the clinical picture at this stage and significantly impact quality of life (Schapira et al., 2017). The management of advanced PD is complex, requiring a multidisciplinary approach and often considering advanced therapies such as deep brain stimulation or continuous dopaminergic drug delivery systems.

5.2. Spread of Pathology in the Brain

5.2.1. Braak Staging System

The Braak staging system provides a framework for understanding the spread of α-synuclein pathology in PD. This system proposes a predictable pattern of disease progression through the brain:

- Stages 1-2 (Prodromal/Early PD): Pathology begins in the dorsal motor nucleus of the vagus nerve, olfactory bulb, and enteric nervous system. This correlates with early non-motor symptoms like hyposmia and constipation (Borghammer & Van Den Berge, 2019).
- Stages 3-4 (Early to Moderate PD): Pathology ascends to the substantia nigra and other midbrain and basal forebrain structures, correlating with the onset of classical motor symptoms due to dopaminergic neuron loss (Jellinger, 2019).
- Stages 5-6 (Advanced PD): α-synuclein pathology spreads to the neocortex, affecting higher-order sensory association and prefrontal areas. This stage correlates with cognitive decline and other advanced symptoms (Jellinger, 2019).

5.2.2. Recent Advances and Challenges to Braak Model:

While the Braak staging system has been influential, recent research has both expanded upon and challenged this model. The Dual-Hit Hypothesis, proposed by Hawkes et al. (2007), suggests that α-synuclein pathology may begin simultaneously in the gut and the olfactory bulb, spreading to the brain through multiple routes. This hypothesis aligns with the early occurrence of olfactory dysfunction and gastrointestinal symptoms in many PD patients.

Another significant advance in understanding PD progression is the concept of prion-like spread. Evidence suggests that misfolded α-synuclein proteins may induce misfolding in neighboring proteins, leading to a propagation of pathology throughout the brain (Brundin & Melki, 2017). This model helps explain the progressive nature of PD and has implications for potential therapeutic strategies aimed at halting disease progression.

Research has also highlighted the concept of selective vulnerability in PD. Not all brain regions are equally susceptible to α-synuclein pathology, with factors such as neuronal type, connectivity, and local environment influencing vulnerability (Surmeier et al., 2017). This selective vulnerability may explain some of the heterogeneity observed in PD progression and symptom manifestation.

The progression of non-motor symptoms in PD doesn't always align with motor symptom progression, suggesting complex underlying pathological processes beyond the simplistic staging models (Schapira et al., 2017).

Furthermore, recent studies have identified distinct PD subtypes with different patterns of progression. For example, tremor-dominant PD often progresses more slowly than akinetic-rigid subtypes (Fereshtehnejad et al., 2019).

Lastly, while α-synuclein pathology is central to PD, other pathological processes also contribute to disease progression. The accumulation of tau protein and vascular changes, for instance, play roles in cognitive decline in PD (Irwin et al., 2013). These findings underscore the complex and multifaceted nature of PD progression, highlighting the need for personalized approaches to patient management and treatment.

6. Clinical Features of Parkinson's Disease

Parkinson's Disease (PD) is characterized by a diverse array of motor and non-motor symptoms. The clinical presentation can vary significantly between individuals and often changes as the disease progresses. Recent research has emphasized the importance of recognizing both motor and non-motor symptoms for accurate diagnosis, effective management, and improved quality of life for patients.

6.1. Motor Symptoms

The cardinal motor symptoms of PD, often referred to as parkinsonism, include:

- Bradykinesia: This refers to slowness of movement and is considered the most characteristic clinical feature of PD. Bradykinesia manifests as difficulties with planning, initiating, and executing movements, as well as with performing sequential and simultaneous tasks. Recent studies have shown that bradykinesia can be objectively measured using wearable sensors, potentially improving diagnosis and monitoring of disease progression (Espay et al., 2016).
- Resting Tremor: A rhythmic, involuntary shaking that occurs when the affected body part is relaxed and supported against gravity. It typically begins unilaterally, often in the hand or foot, and is characterized by a frequency of 4-6 Hz. While tremor is often considered the most recognizable sign of PD, it is important to note that not all PD patients develop tremor (Bhatia et al., 2018).
- Rigidity: An increased resistance to passive movement of the limbs. It can be smooth ("lead-pipe" rigidity) or ratchety ("cogwheel" rigidity when combined with tremor). Rigidity can contribute to pain and stiffness, particularly in the neck and shoulder regions (Kwon et al., 2014).
- Postural Instability: This typically occurs in later stages of the disease and manifests as impaired balance and an increased risk of falls. Recent research has highlighted the complex interplay between motor and non-motor factors (such as cognitive impairment and anxiety) in contributing to postural instability (Pantall et al., 2018).

6.1.1. Additional motor symptoms include

- Gait disturbances: Including shuffling gait, festination (rapid, small steps), and freezing of gait (Nonnekes et al., 2015).
- Micrographia: Abnormally small or cramped handwriting.
- Hypomimia: Reduced facial expressiveness, often described as a "mask-like" appearance.
- Speech changes: Including hypophonia (soft speech), monotone, and dysarthria.

6.2. Non-Motor Symptoms

In recent years, there has been increasing recognition of the importance of non-motor symptoms in PD. These symptoms can significantly impact quality of life and often precede the onset of motor symptoms. Key non-motor features include:

- Cognitive Impairment: Ranging from mild cognitive impairment to dementia. Executive function, attention, and visuospatial ability are commonly affected. Recent research has highlighted the heterogeneity of cognitive profiles in PD and the potential role of biomarkers in predicting cognitive decline (Williams-Gray et al., 2018).
- Neuropsychiatric Symptoms:
  - Depression: Affects up to 35% of PD patients and is associated with worse quality of life and faster disease progression (Zhu et al., 2016).
  - Anxiety: Common in PD, often coexisting with depression and contributing to motor symptoms like freezing of gait (Ehgoetz Martens et al., 2018).
  - Apathy: Increasingly recognized as a distinct neuropsychiatric symptom in PD, associated with cognitive impairment and poor outcomes (den Brok et al., 2015).
  - Psychosis: Including visual hallucinations and delusions, more common in advanced disease and associated with cognitive impairment (Ffytche et al., 2017).
- Sleep Disorders:
  - REM sleep behavior disorder (RBD): Often precedes the motor symptoms of PD by years and is now recognized as a strong prodromal marker (Postuma et al., 2019).
  - Insomnia: Common in PD, often multifactorial in origin (Zhu et al., 2016).
  - Excessive daytime sleepiness: Can be a feature of the disease itself or a side effect of dopaminergic medications (Amara et al., 2017).
- Autonomic Dysfunction:
  - Orthostatic hypotension: Associated with falls and cognitive impairment (Merola et al., 2018).
  - Gastrointestinal symptoms: Including constipation (often preceding motor symptoms), dysphagia, and delayed gastric emptying (Fasano et al., 2015).
  - Urinary symptoms: Such as nocturia, frequency, and urgency (Roy et al., 2019).
  - Sexual dysfunction: Including erectile dysfunction and decreased libido (Bronner et al., 2015).
- Sensory Symptoms:

    - Hyposmia: Reduced sense of smell, often preceding motor symptoms and now recognized as a prodromal feature of PD (Fullard et al., 2017).
    - Pain: A common but often underrecognized feature of PD, with various presentations including musculoskeletal, dystonic, and central pain (Mijatovic et al., 2018).
- Fatigue: A common and disabling symptom, often independent of motor severity and sleep disorders (Stocchi et al., 2014).

Recent research has emphasized the heterogeneity of PD, with different subtypes showing varying predominance of motor and non-motor symptoms. For example, the tremor-dominant subtype tends to have a more benign course with slower progression of both motor and non-motor symptoms, while the postural instability gait difficulty (PIGD) subtype is associated with more rapid progression and a higher risk of cognitive impairment (Fereshtehnejad et al., 2015).

Understanding the full spectrum of motor and non-motor symptoms in PD is crucial for accurate diagnosis, effective management, and improved quality of life for patients. Ongoing research continues to refine our understanding of these symptoms and their underlying mechanisms, paving the way for more personalized and comprehensive treatment approaches.

7. Emerging Research Areas and Potential New Therapeutic Targets in Parkinson's Disease

As our understanding of Parkinson's Disease (PD) continues to evolve, several exciting research areas have emerged, offering new insights into disease mechanisms and potential therapeutic targets. These areas of investigation hold promise for developing novel treatments that may slow or halt disease progression, rather than merely alleviating symptoms.

7.1. Alpha-Synuclein Targeting Therapies

Alpha-synuclein aggregation is a hallmark of PD pathology. Recent research has focused on developing therapies to reduce alpha-synuclein accumulation or spread:

- Immunotherapies: Both active and passive immunization strategies against alpha-synuclein are being explored. A phase 2 trial of the active immunotherapy PD01A showed good safety and tolerability (Volc et al., 2020).
- Small Molecules: Compounds that inhibit alpha-synuclein aggregation or enhance its clearance are under investigation. For instance, anle138b has shown promise in preclinical models by reducing alpha-synuclein oligomerization (Wagner et al., 2013).

7.2. Targeting Neuroinflammation

Chronic neuroinflammation plays a crucial role in PD progression. Several approaches are being explored to modulate the inflammatory response:

- Microglial Modulation: Inhibitors of microglial activation, such as PLX3397 (a CSF1R inhibitor), have shown neuroprotective effects in animal models of PD (Zhu et al., 2020).
- Anti-inflammatory Drugs: Repurposing of existing anti-inflammatory drugs, such as exenatide (a GLP-1 receptor agonist), has shown potential neuroprotective effects in clinical trials (Athauda et al., 2017).

7.2.1. Mitochondrial Dysfunction and Oxidative Stress

Mitochondrial dysfunction and oxidative stress are key contributors to dopaminergic neuron loss in PD. Novel approaches include:

- Mitochondrial-Targeted Antioxidants: Compounds like MitoQ, which selectively accumulate in mitochondria, have shown promise in preclinical studies (Forkink et al., 2018).
- PPAR Agonists: Peroxisome proliferator-activated receptor (PPAR) agonists, such as pioglitazone, are being investigated for their potential to improve mitochondrial function and reduce inflammation (Halliday & Schuele, 2018).

7.2.2. Gut-Brain Axis

The role of the gut-brain axis in PD pathogenesis is an exciting area of research:

- Microbiome Modulation: Probiotics and prebiotics are being studied for their potential to influence PD progression through modulation of the gut microbiome (Lubomski et al., 2019).
- Enteric Nervous System: Targeting alpha-synuclein aggregation in the enteric nervous system is being explored as a potential early intervention strategy (Barbut et al., 2019).

7.2.3. Neuroprotective Gene Therapies

Advances in gene therapy techniques have opened new avenues for neuroprotection in PD:

- DNF and NRTN: Delivery of neurotrophic factors like glial cell
- line-derived neurotrophic factor (GDNF) and neurturin (NRTN) using viral vectors has shown promise in preclinical studies and early clinical trials (Holtmeier et al., 2020).
- GBA Gene Therapy: Given the importance of GBA mutations in PD risk, gene therapy approaches to increase glucocerebrosidase activity are being explored (Sardi et al., 2020).

7.2.4. Repurposing Existing Drugs

Repurposing of drugs approved for other indications is an active area of research:

- Diabetes Drugs: GLP-1 receptor agonists like exenatide and liraglutide have shown potential neuroprotective effects in PD models and clinical trials (Athauda et al., 2017).
- Tyrosine Kinase Inhibitors: Drugs like nilotinib, used in cancer treatment, are being investigated for their potential to enhance autophagy and reduce alpha-synuclein accumulation (Pagan et al., 2020).

7.2.5. Circadian Rhythm Modulation

Disruption of circadian rhythms is common in PD and may contribute to disease progression:

- Light Therapy: Bright light therapy is being studied for its potential to improve both motor and non-motor symptoms in PD (Videnovic et al., 2017).
- Melatonin: The role of melatonin in neuroprotection and circadian rhythm regulation in PD is under investigation (Escames et al., 2019).

7.2.6. Precision Medicine Approaches

There is growing interest in developing personalized treatment strategies based on individual patient characteristics:

- Genetic Profiling: Tailoring treatments based on a patient's genetic profile, particularly for those with known PD-associated mutations (Robb et al., 2020).
- Biomarker-Guided Therapy: Using biomarkers to predict disease progression and treatment response, allowing for more targeted interventions (Mollenhauer et al., 2020).

These emerging research areas represent a shift towards targeting the underlying disease processes in PD, rather than just managing symptoms. While many of these approaches are still in early stages of development, they offer hope for more effective treatments that could slow or halt disease progression. As our understanding of PD pathogenesis continues to grow, it is likely that combination therapies targeting multiple pathways will be necessary to effectively combat this complex neurodegenerative disorder.

8. Conclusion

Parkinson's Disease (PD) is a complex neurodegenerative disorder with multifaceted pathophysiology involving genetic, environmental, and age-related factors. Our understanding of PD has evolved significantly, revealing intricate molecular and cellular mechanisms underlying its progression. Key areas of focus include alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, neuroinflammation, and the gut-brain axis. The heterogeneity of PD, both in its clinical presentation and underlying pathology, underscores the need for personalized approaches to diagnosis and treatment.

Emerging research areas, such as alpha-synuclein targeting therapies, neuroprotective gene therapies, and precision medicine approaches, offer promising avenues for developing more effective treatments. These strategies aim not only to alleviate symptoms but also to slow or halt disease progression. As our understanding of PD continues to grow, it is

likely that combination therapies targeting multiple pathways will be necessary to effectively combat this complex disorder.

The future of PD research and treatment lies in integrating our knowledge of genetics, molecular pathways, and environmental factors to develop tailored interventions. This comprehensive approach, coupled with early detection and intervention strategies, holds the potential to significantly improve outcomes for individuals with PD. Continued multidisciplinary research efforts are crucial to unravel the remaining mysteries of PD pathogenesis and to translate these insights into tangible benefits for patients.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Amara, A. W., Chahine, L. M., & Videnovic, A. (2017). Treatment of sleep dysfunction in Parkinson's disease. Current Treatment Options in Neurology, 19(7), 26.

[2] Ascherio, A., & Schwarzschild, M. A. (2016). The epidemiology of Parkinson's disease: risk factors and prevention. The Lancet Neurology, 15(12), 1257-1272.

[3] Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., ... & Foltynie, T. (2017). Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. The Lancet, 390(10103), 1664-1675.

[4] Barbut, D., Stolzenberg, E., & Zasloff, M. (2019). Gastrointestinal immunity and alpha-synuclein. Journal of Parkinson's Disease, 9(s2), S313-S322.

[5] Beal, M. F. (2003). Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Annals of the New York Academy of Sciences, 991(1), 120-131.

[6] Beauchamp, L. C., Finkelstein, D. I., Bush, A. I., Evans, A. H., & Barnham, K. J. (2020). Parkinsonism as a Third Wave of the COVID-19 Pandemic? Journal of Parkinson's Disease, 10(4), 1343-1353.

[7] Bhatia, K. P., Bain, P., Bajaj, N., Elble, R. J., Hallett, M., Louis, E. D., ... & Tremor Task Force of the International Parkinson and Movement Disorder Society. (2018). Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Movement Disorders, 33(1), 75-87.

[8] Bjorklund, G., Stejskal, V., Urbina, M. A., Dadar, M., Chirumbolo, S., & Mutter, J. (2018). Metals and Parkinson's disease: Mechanisms and biochemical processes. Current Medicinal Chemistry, 25(19), 2198-2214.

[9] Blauwendraat, C., Nalls, M. A., & Singleton, A. B. (2020). The genetic architecture of Parkinson's disease. The Lancet Neurology, 19(2), 170-178.

[10] Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson's disease. The Lancet, 397(10291), 2284-2303.

[11] Boertien, J. M., Pereira, P. A. B., Aho, V. T. E., & Scheperjans, F. (2019). Increasing comparability and utility of gut microbiome studies in Parkinson's disease: A systematic review. Journal of Parkinson's Disease, 9(s2), S297-S312.

[12] Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., ... & Heutink, P. (2003). Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 299(5604), 256-259.

[13] Borghammer, P., & Van Den Berge, N. (2019). Brain-first versus gut-first Parkinson's disease: a hypothesis. Journal of Parkinson's Disease, 9(s2), S281-S295.

[14] Braak, H., Del Tredici, K., Rüb, U., de Vos, R. A., Steur, E. N. J., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging, 24(2), 197-211.

[15] Bronner, G., Royter, V., Korczyn, A. D., & Giladi, N. (2015). Sexual dysfunction in Parkinson's disease. Journal of Sex & Marital Therapy, 30(2), 95-105.

[16] Brundin, P., & Melki, R. (2017). Prying into the prion hypothesis for Parkinson's disease. Journal of Neuroscience, 37(41), 9808-9818.

[17] Cagnan, H., Mallet, N., Moll, C. K., Gulberti, A., Holt, A. B., Westphal, M., ... & Engel, A. K. (2019). Temporal evolution of beta bursts in the parkinsonian cortical and basal ganglia network. Proceedings of the National Academy of Sciences, 116(32), 16095-16104.

[18] Calabresi, P., Picconi, B., Tozzi, A., Ghiglieri, V., & Di Filippo, M. (2013). Direct and indirect pathways of basal ganglia: a critical reappraisal. Nature Neuroscience, 16(8), 1022-1030.

[19] Challis, C., Hori, A., Sampson, T. R., Yoo, B. B., Challis, R. C., Hamilton, A. M.,... & Mazmanian, S. K. (2020). Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice. Nature Neuroscience, 23(3), 327-336.

[20] Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006). Non-motor symptoms of Parkinson's disease: diagnosis and management. The Lancet Neurology, 5(3), 235-245.

[21] Chen, H., Kwong, J. C., Copes, R., Tu, K., Villeneuve, P. J., van Donkelaar, A.,... & Burnett, R. T. (2017). Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study. The Lancet, 389(10070), 718-726.

[22] Chin-Chan, M., Navarro-Yepes, J., & Quintanilla-Vega, B. (2015). Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Frontiers in Cellular Neuroscience, 9, 124.

[23] Chuang, Y. H., Paul, K. C., Bronstein, J. M., Bordelon, Y., Horvath, S., & Ritz, B. (2017). Parkinson's disease is associated with DNA methylation levels in human blood and saliva. Genome Medicine, 9(1), 76.

[24] Cookson, M. R. (2015). LRRK2 pathways leading to neurodegeneration. Current Neurology and Neuroscience Reports, 15(7), 42.

[25] Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., ... & Dinkova-Kostova, A. T. (2018). Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nature Reviews Drug Discovery, 17(9), 709-727.

[26] Dangerfield, A. L. (2021). Melatonin as a circadian molecule for treating sleep disorders in Parkinson's disease. Movement Disorders Clinical Practice, 8(3), 314-315.

[27] den Brok, M. G., van Dalen, J. W., van Gool, W. A., Moll van Charante, E. P., de Bie, R. M., & Richard, E. (2015). Apathy in Parkinson's disease: A systematic review and meta-analysis. Movement Disorders, 30(6), 759-769.

[28] Di Maio, R., Barrett, P. J., Hoffman, E. K., Barrett, C. W., Zharikov, A., Borah, A., ... & Greenamyre, J. T. (2018). α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. Science Translational Medicine, 10(444), eaar5748.

[29] Dias, V., Junn, E., & Mouradian, M. M. (2013). The role of oxidative stress in Parkinson's disease. Journal of Parkinson's Disease, 3(4), 461-491.

[30] Dorsey, E. R., Elbaz, A., Nichols, E., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., ... & Murray, C. J. L. (2018). Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 17(11), 939-953.

[31] Ehgoetz Martens, K. A., Hall, J. M., Gilat, M., Georgiades, M. J., Walton, C. C., & Lewis, S. J. (2016). Anxiety is associated with freezing of gait and attentional set-shifting in Parkinson's disease: A new perspective for early intervention. Gait & Posture, 49, 431-436.

[32] Emamzadeh, F. N. (2016). Alpha-synuclein structure, functions, and interactions. Journal of Research in Medical Sciences, 21, 29.

[33] Emre, M., Poewe, W., De Deyn, P. P., Barone, P., Kulisevsky, J., Pourcher, E., ... & Lane, R. (2014). Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study. Clinical Neuropharmacology, 37(1), 9-16.

[34] Escames, G., Gomez-Cabrera, M. D. C., & Acuña-Castroviejo, D. (2019). Melatonin role in neurodegenerative diseases: Potential therapeutic approaches. Melatonin: The Hormone of Darkness and its Therapeutic Potential and Perspectives, 176-189.

[35] Espay, A. J., Bonato, P., Nahab, F. B., Maetzler, W., Dean, J. M., Klucken, J., ... & Movement Disorders Society Task Force on Technology. (2016). Technology in Parkinson's disease: Challenges and opportunities. Movement Disorders, 31(9), 1272-1282.

[36] Fang, X., Han, D., Cheng, Q., Zhang, P., Zhao, C., Min, J., & Wang, F. (2018). Association of levels of physical activity with risk of Parkinson disease: A systematic review and meta-analysis. JAMA Network Open, 1(5), e182421.

[37] Fasano, A., Visanji, N. P., Liu, L. W., Lang, A. E., & Pfeiffer, R. F. (2015). Gastrointestinal dysfunction in Parkinson's disease. The Lancet Neurology, 14(6), 625-639.

[38] Fereshtehnejad, S. M., Romenets, S. R., Anang, J. B., Latreille, V., Gagnon, J. F., & Postuma, R. B. (2015). New clinical subtypes of Parkinson disease and their longitudinal progression: A prospective cohort comparison with other phenotypes. JAMA Neurology, 72(8), 863-873.

[39] Fereshtehnejad, S. M., Zeighami, Y., Dagher, A., & Postuma, R. B. (2019). Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Brain, 142(12), 3566-3583.

[40] Ffytche, D. H., Creese, B., Politis, M., Chaudhuri, K. R., Weintraub, D., Ballard, C., & Aarsland, D. (2017). The psychosis spectrum in Parkinson disease. Nature Reviews Neurology, 13(2), 81-95.

[41] Flagmeier, P., Meisl, G., Vendruscolo, M., Knowles, T. P., Dobson, C. M., Buell, A. K., & Galvagnion, C. (2017). Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of α-synuclein aggregation. Proceedings of the National Academy of Sciences, 114(37), 10045-10050.

[42] Fonseca, S. B., Pereira, M. P., & Kelley, S. O. (2019). Recent advances in the use of mitochondria-targeted antioxidants to treat neurodegenerative diseases. Advanced Drug Delivery Reviews, 146, 235-251.

[43] Forkink, M., Basit, F., Teixeira, J., Swarts, H. G., Koopman, W. J., & Willems, P. H. (2018). Complex I and complex III inhibition specifically increase cytosolic hydrogen peroxide levels without inducing oxidative stress in HEK293 cells. Redox Biology, 15, 129-139.

[44] Fullard, M. E., Morley, J. F., & Duda, J. E. (2017). Olfactory dysfunction as an early biomarker in Parkinson's disease. Neuroscience Bulletin, 33(5), 515-525.

[45] Galvan, A., Devergnas, A., & Wichmann, T. (2021). Alterations in neuronal activity in basal ganglia-thalamocortical circuits in the parkinsonian state. Nature Neuroscience, 24(11), 1335-1346.

[46] Galvan, A., & Wichmann, T. (2007). GABAergic circuits in the basal ganglia and movement disorders. Progress in Brain Research, 160, 287-312.

[47] Gardner, R. C., Byers, A. L., Barnes, D. E., Li, Y., Boscardin, J., & Yaffe, K. (2018). Mild TBI and risk of Parkinson disease: A chronic effects of neurotrauma consortium study. Neurology, 90(20), e1771-e1779.

[48] GBD 2016 Neurology Collaborators. (2018). Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 17(11), 939-953.

[49] Gelders, G., Baekelandt, V., & Van der Perren, A. (2018). Linking neuroinflammation and neurodegeneration in Parkinson's disease. Journal of Immunology Research, 2018, 4784268.

[50] Gillies, G. E., Pienaar, I. S., Vohra, S., & Qamhawi, Z. (2014). Sex differences in Parkinson's disease. Frontiers in Neuroendocrinology, 35(3), 370-384.

[51] Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L., & Richardson, R. J. (1998). The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology, 50(5), 1346-1350.

[52] Grandinetti, A., Morens, D. M., Reed, D., & MacEachern, D. (1996). Occupational exposure to metals and risk of Parkinson's disease. Neuroepidemiology, 15(2), 87-94.

[53] Gunnarsson, L. G., & Bodin, L. (2019). Occupational exposures and neurodegenerative diseases—A systematic literature review and meta-analyses. International Journal of Environmental Research and Public Health, 16(3), 337.

[54] Halliday, G., & Schuele, S. U. (2018). The role of peroxisome proliferator-activated receptors in Parkinson's disease. Journal of Neural Transmission, 125(6), 809-815.

[55] Harms, A. S., Thome, A. D., Yan, Z., Schonhoff, A. M., Williams, G. P., Li, X., ... & Standaert, D. G. (2021). Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease. Experimental Neurology, 340, 113596.

[56] Hawkes, C. H., Del Tredici, K., & Braak, H. (2007). Parkinson's disease: a dual-hit hypothesis. Neuropathology and Applied Neurobiology, 33(6), 599-614.

[57] Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., ... & Wood, N. W. (2008). Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. The Lancet Neurology, 7(7), 583-590.

[58] Heinzel, S., Berg, D., Gasser, T., Chen, H., Yao, C., & Postuma, R. B. (2019). Update of the MDS research criteria for prodromal Parkinson's disease. Movement Disorders, 34(10), 1464-1470.

[59] Henchcliffe, C., & Beal, M. F. (2008). Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nature Clinical Practice Neurology, 4(11), 600-609.

[60] Hirsch, L., Jette, N., Frolkis, A., Steeves, T., & Pringsheim, T. (2016). The incidence of Parkinson's disease: a systematic review and meta-analysis. Neuroepidemiology, 46(4), 292-300.

[61] Holtmeier, J., Kordower, J. H., & Bartus, R. T. (2020). Gene therapy for Parkinson's disease: Translational approaches using fluorescent imaging and behavioral assessment in nonhuman primates. Neurobiology of Disease, 135, 104721.

[62] Hughes, K. C., Gao, X., Kim, I. Y., Wang, M., Weisskopf, M. G., Schwarzschild, M. A., & Ascherio, A. (2017). Intake of dairy foods and risk of Parkinson disease. Neurology, 89(1), 46-52.

[63] Irwin, D. J., Lee, V. M. Y., & Trojanowski, J. Q. (2013). Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nature Reviews Neuroscience, 14(9), 626-636.

[64] Jafari, S., Etminan, M., Aminzadeh, F., & Samii, A. (2020). Head injury and risk of Parkinson disease: A systematic review and meta-analysis. Movement Disorders, 35(2), 212-219.

[65] Jain, S. K., Langham, M. C., & Wehrli, F. W. (2013). MRI estimation of global brain oxygen consumption rate. Journal of Cerebral Blood Flow & Metabolism, 33(10), 1521-1525.

[66] Jellinger, K. A. (2019). Is Braak staging valid for all types of Parkinson's disease? Journal of Neural Transmission, 126(4), 423-431.

[67] Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. The Lancet, 386(9996), 896-912.

[68] Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., ... & Shannon, K. M. (2015). Colonic bacterial composition in Parkinson's disease. Movement Disorders, 30(10), 1351-1360.

[69] Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., ... & Shimizu, N. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392(6676), 605-608.

[70] Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., ... & Bartus, R. T. (2013). Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain, 136(8), 2419-2431.

[71] Kouli, A., Camacho, M., Allinson, K., & Williams-Gray, C. H. (2020). Neuroinflammation and protein pathology in Parkinson's disease dementia. Acta Neuropathologica Communications, 8(1), 211.

[72] Kwon, K. Y., Lee, H. M., Lee, S. M., Kang, S. H., & Koh, S. B. (2016). Comparison of motor and non-motor features between essential tremor and tremor dominant Parkinson's disease. Journal of the Neurological Sciences, 361, 34-38.

[73] Li, X., Li, W., Liu, G., Shen, X., & Tang, Y. (2015). Association between cigarette smoking and Parkinson's disease: A meta-analysis. Archives of Gerontology and Geriatrics, 61(3), 510-516.

[74] Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., ... & Barres, B. A. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature, 541(7638), 481-487.

[75] Little, S., & Brown, P. (2014). The functional role of beta oscillations in Parkinson's disease. Parkinsonism & Related Disorders, 20, S44-S48.

[76] Liu, R., Young, M. T., Chen, J. C., Kaufman, J. D., & Chen, H. (2016). Ambient air pollution exposures and risk of Parkinson disease. Environmental Health Perspectives, 124(11), 1759-1765.

[77] Lubomski, M., Tan, A. H., Lim, S. Y., Holmes, A. J., Davis, R. L., & Sue, C. M. (2019). Parkinson's disease and the gastrointestinal microbiome. Journal of Neurology, 266(11), 2622-2634.

[78] Lucchini, R. G., Guazzetti, S., Zoni, S., Donna, F., Peter, S., Zacco, A., ... & Smith, D. R. (2021). Tremor, olfactory and motor changes in Italian adolescents exposed to historical ferro-manganese emission. Neurotoxicology, 83, 212-221.

[79] Marras, C., Canning, C. G., & Goldman, S. M. (2016). Environment, lifestyle, and Parkinson's disease: Implications for prevention in the next decade. Movement Disorders, 31(1), 8-14.

[80] Mena-Segovia, J., Bolam, J. P., & Magill, P. J. (2004). Pedunculopontine nucleus and basal ganglia: distant relatives or part of the same family? Trends in Neurosciences, 27(10), 585-588.

[81] Merola, A., Romagnolo, A., Rosso, M., Lopez-Castellanos, J. R., Wissel, B. D., Larkin, S., ... & Espay, A. J. (2018). Orthostatic hypotension in Parkinson's disease: Impact on health care utilization. Parkinsonism & Related Disorders, 47, 45-49.

[82] Metcalfe-Roach, A., Yu, A. C., Golz, E., Cirstea, M., Sundvick, K., Kliger, D., ... & Gibson, E. (2021). MIND and Mediterranean diets associated with later onset of Parkinson's disease. Movement Disorders, 36(4), 977-984.

[83] Mijatovic, L., Jankovic, M., Jovic, J., & Covickovic-Sternic, N. (2018). Pain in Parkinson's disease: New concepts in pathogenesis and treatment. Current Topics in Medicinal Chemistry, 18(7), 2251-2265.

[84] Mollenhauer, B., Zimmermann, J., Sixel-Döring, F., Focke, N. K., Wicke, T., Ebentheuer, J., ... & DeNoPa Study Group. (2020). Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Movement Disorders, 35(9), 1597-1608.

[85] Mortiboys, H., Furmston, R., Bronstad, G., Aasly, J., Elliott, C., & Bandmann, O. (2015). UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2 G2019S carriers and in vivo. Neurology, 85(10), 846-852.

[86] Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., ... & Singleton, A. B. (2019). Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. The Lancet Neurology, 18(12), 1091-1102.

[87] Nambu, A., Tokuno, H., & Takada, M. (2002). Functional significance of the cortico–subthalamo–pallidal 'hyperdirect' pathway. Neuroscience Research, 43(2), 111-117.

[88] Nandipati, S., & Litvan, I. (2016). Environmental exposures and Parkinson's disease. International Journal of Environmental Research and Public Health, 13(9), 881.

[89] Nonnekes, J., Snijders, A. H., Nutt, J. G., Deuschl, G., Giladi, N., & Bloem, B. R. (2015). Freezing of gait: A practical approach to management. The Lancet Neurology, 14(7), 768-778.

[90] Noyce, A. J., Bestwick, J. P., Silveira-Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. (2012). Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Annals of Neurology, 72(6), 893-901.

[91] Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., ... & Stoessl, A. J. (2017). Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders, 32(9), 1264-1310.

[92] Olanow, C. W., Kieburtz, K., Odin, P., Espay, A. J., Standaert, D. G., Fernandez, H. H., ... & Antonini, A. (2020). Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. The Lancet Neurology, 13(2), 141-149.

[93] Pagan, F. L., Hebron, M. L., Wilmarth, B., Torres-Yaghi, Y., Lawler, A., Mundel, E. E., ... & Moussa, C. (2020). Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: A phase 2 randomized clinical trial. JAMA Neurology, 77(3), 309-317.

[94] Pantall, A., Suresparan, P., Kapa, L., Morris, R., Yarnall, A., Del Din, S., & Rochester, L. (2018). Postural dynamics are associated with cognitive decline in Parkinson's disease. Frontiers in Neurology, 9, 1044.

[95] Parashos, S. A., Wielinski, C. L., & Kern, J. A. (2014). Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease. Clinical Neuropharmacology, 27(3), 119-123.

[96] Parkinson, J. (1817). An essay on the shaking palsy. London: Whittingham and Rowland.

[97] Perier, C., Bové, J., Dehay, B., Jackson-Lewis, V., Rabinovitch, P. S., Przedborski, S., & Vila, M. (2020). Apoptosis-inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins. Annals of Neurology, 68(2), 184-192.

[98] Pickles, S., Vigié, P., & Youle, R. J. (2018). Mitophagy and quality control mechanisms in mitochondrial maintenance. Current Biology, 28(4), R170-R185.

[99] Pickrell, A. M., & Youle, R. J. (2015). The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron, 85(2), 257-273.

[100] Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., ... & Lang, A. E. (2017). Parkinson disease. Nature Reviews Disease Primers, 3(1), 1-21.

[101] Politis, M., Wu, K., Loane, C., Kiferle, L., Molloy, S., Brooks, D. J., & Piccini, P. (2010). Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiology of Disease, 40(1), 216-221.

[102] Postuma, R. B., Iranzo, A., Hu, M., Högl, B., Boeve, B. F., Manni, R., ... & Pelletier, A. (2019). Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: A multicentre study. Brain, 142(3), 744-759.

[103] Poulin, J. F., Caronia, G., Hofer, C., Cui, Q., Helm, B., Ramakrishnan, C., ... & Awatramani, R. (2018). Mapping projections of molecularly defined dopamine neuron subtypes using intersectional genetic approaches. Nature Neuroscience, 21(9), 1260-1271.

[104] Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. (2014). The prevalence of Parkinson's disease: A systematic review and meta-analysis. Movement Disorders, 29(13), 1583-1590.

[105] Priyadarshi, A., Khuder, S. A., Schaub, E. A., & Priyadarshi, S. S. (2001). Environmental risk factors and Parkinson's disease: A metaanalysis. Environmental Research, 86(2), 122-127.

[106] Puschmann, A. (2013). Monogenic Parkinson's disease and parkinsonism: Clinical phenotypes and frequencies of known mutations. Parkinsonism & Related Disorders, 19(4), 407-415.

[107] Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., ... & Kubisch, C. (2006). Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nature Genetics, 38(10), 1184-1191.

[108] Reeve, A., Simcox, E., & Turnbull, D. (2014). Ageing and Parkinson's disease: Why is advancing age the biggest risk factor? Ageing Research Reviews, 14, 19-30.

[109] Ren, L., Yi, J., Yang, J., Li, P., Cheng, X., & Mao, P. (2020). Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: A dose–response meta-analysis. Medicine, 99(5), e18884.

[110] Repici, M., & Giorgini, F. (2019). DJ-1 in Parkinson's disease: Clinical insights and therapeutic perspectives. Journal of Clinical Medicine, 8(9), 1377.

[111] Robb, E. L., Dos Santos, L. A., Kalia, S. K., & Kalia, L. V. (2020). Genetic risk factors for Parkinson's disease: Implications for personalized medicine. Journal of Personalized Medicine, 10(4), 224.

[112] Robak, L. A., Jansen, I. E., Van Rooij, J., Uitterlinden, A. G., Kraaij, R., Jankovic, J., ... & Shulman, J. M. (2017). Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. Brain, 140(12), 3191-3203.

[113] Romano, S., Savva, G. M., Bedarf, J. R., Charles, I. G., Hildebrand, F., & Narbad, A. (2021). Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinson's Disease, 7(1), 27.

[114] Roy, H. A., Aziz, T. Z., Fitzgerald, J. J., & Green, A. L. (2019). Beta oscillations and urinary voiding in Parkinson disease. Neurology, 92(11), e1207-e1216.

[115] Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., ... & Mazmanian, S. K. (2016). Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell, 167(6), 1469-1480.

[116] Sardi, S. P., Cedarbaum, J. M., & Brundin, P. (2020). Targeted therapies for Parkinson's disease: From genetics to the clinic. Movement Disorders, 35(7), 1047-1048.

[117] Savitt, D., & Jankovic, J. (2019). Targeting α-synuclein in Parkinson's disease: Progress towards the development of disease-modifying therapeutics. Drugs, 79(8), 797-810.

[118] Schapira, A. H., Chaudhuri, K. R., & Jenner, P. (2017). Non-motor features of Parkinson disease. Nature Reviews Neuroscience, 18(7), 435-450.

[119] Segura-Aguilar, J., Paris, I., Muñoz, P., Ferrari, E., Zecca, L., & Zucca, F. A. (2014). Protective and toxic roles of dopamine in Parkinson's disease. Journal of Neurochemistry, 129(6), 898-915.

[120] Seppi, K., Ray Chaudhuri, K., Coelho, M., Fox, S. H., Katzenschlager, R., Perez Lloret, S., ... & Sampaio, C. (2019). Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. Movement Disorders, 34(2), 180-198.

[121] Shih, I. F., Liew, Z., Krause, N., & Ritz, B. (2016). Lifetime occupational and leisure time physical activity and risk of Parkinson's disease. Parkinsonism & Related Disorders, 28, 112-117.

[122] Sidransky, E., & Lopez, G. (2012). The link between the GBA gene and parkinsonism. The Lancet Neurology, 11(11), 986-998.

[123] Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., ... & Ziegler, S. G. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. New England Journal of Medicine, 361(17), 1651-1661.

[124] Spillantini, M. G., Schmidt, M. L., Lee, V. M. Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997). α-Synuclein in Lewy bodies. Nature, 388(6645), 839-840.

[125] Stefanis, L. (2012). α-Synuclein in Parkinson's disease. Cold Spring Harbor Perspectives in Medicine, 2(2), a009399.

[126] Stocchi, F., Abbruzzese, G., Ceravolo, R., Cortelli, P., D'Amelio, M., De Pandis, M. F., ... & Zappia, M. (2014). Prevalence of fatigue in Parkinson disease and its clinical correlates. Neurology, 83(3), 215-220.

[127] Subramaniam, S. R., & Federoff, H. J. (2017). Targeting microglial activation states as a therapeutic avenue in Parkinson's disease. Frontiers in Aging Neuroscience, 9, 176.

[128] Subhramanyam, C. S., Wang, C., Hu, Q., & Dheen, S. T. (2019). Microglia-mediated neuroinflammation in neurodegenerative diseases. Seminars in Cell & Developmental Biology, 94, 112-120.

[129] Sulzer, D., Alcalay, R. N., Garretti, F., Cote, L., Kanter, E., Agin-Liebes, J., ... & Przedborski, S. (2017). T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature, 546(7660), 656-661.

[130] Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017). Selective neuronal vulnerability in Parkinson disease. Nature Reviews Neuroscience, 18(2), 101-113.

[131] Tan, E. K., Srivastava, A. K., Arnold, W. D., Singh, M. P., & Zhang, Y. (2019). Frequency of LRRK2 mutations in late-onset Parkinson's disease. Movement Disorders, 34(12), 1795-1796.

[132] Tanner, C. M., Kamel, F., Ross, G. W., Hoppin, J. A., Goldman, S. M., Korell, M., ... & Langston, J. W. (2011). Rotenone, paraquat, and Parkinson's disease. Environmental Health Perspectives, 119(6), 866-872.

[133] Valdinocci, D., Alavi Naini, S. M., & Pountney, D. L. (2021). Mitochondrial dysfunction and autophagy in Parkinson's disease. Frontiers in Molecular Neuroscience, 14, 673239.

[134] Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M., Harvey, K., Gispert, S., ... & Wood, N. W. (2004). Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science, 304(5674), 1158-1160.

[135] Van Den Eeden, S. K., Tanner, C. M., Bernstein, A. L., Fross, R. D., Leimpeter, A., Bloch, D. A., & Nelson, L. M. (2003). Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. American Journal of Epidemiology, 157(11), 1015-1022.

[136] Van Kessel, S. P., & El Aidy, S. (2019). Bacterial metabolites mirror altered gut microbiota composition in patients with Parkinson's disease. Journal of Parkinson's Disease, 9(s2), S359-S370.

[137] van Veen, S., Martin, S., Van den Haute, C., Benoy, V., Lyons, J., Vanhoutte, R., ... & Vangheluwe, P. (2020). ATP13A2 deficiency disrupts lysosomal polyamine export. Nature, 578(7795), 419-424.

[138] Videnovic, A., Klerman, E. B., Wang, W., Marconi, A., Kuhta, T., & Zee, P. C. (2017). Timed light therapy for sleep and daytime sleepiness associated with Parkinson disease: A randomized clinical trial. JAMA Neurology, 74(4), 411-418.

[139] Volc, D., Poewe, W., Kutzelnigg, A., Lührs, P., Thun-Hohenstein, C., Schneeberger, A., ... & Stefanova, N. (2020). Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: A randomised, single-blinded, phase 1 trial. The Lancet Neurology, 19(7), 591-600.

[140] Wagner, J., Ryazanov, S., Leonov, A., Levin, J., Shi, S., Schmidt, F., ... & Giese, A. (2013). Anle138b: A novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathologica, 125(6), 795-813.

[141] West, A. B. (2017). Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Experimental Neurology, 298, 236-245.

[142] Williams-Gray, C. H., Evans, J. R., Goris, A., Foltynie, T., Ban, M., Robbins, T. W., ... & Barker, R. A. (2018). The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain, 132(11), 2958-2969.

[143] Willis, A. W., Schootman, M., Kung, N., Evanoff, B. A., Perlmutter, J. S., & Racette, B. A. (2019). Epidemiological trends in the rate of Parkinson disease diagnoses over the past 30 years in the United States. Movement Disorders, 34(11), 1732-1736.

[144] Wong, Y. C., & Krainc, D. (2017). α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nature Medicine, 23(2), 1-13.

[145] Yan, D., Zhang, Y., Liu, L., & Yan, H. (2018). Pesticide exposure and risk of Parkinson's disease: Dose-response meta-analysis of observational studies. Regulatory Toxicology and Pharmacology, 96, 57-63.

[146] Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., & Mizuno, Y. (1996). Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proceedings of the National Academy of Sciences, 93(7), 2696-2701.

[147] Zabetian, C. P., Hutter, C. M., Factor, S. A., Nutt, J. G., Higgins, D. S., Griffith, A., ... & Payami, H. (2007). Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Annals of Neurology, 62(2), 137-144.

[148] Zhang, C. W., Hang, L., Yao, T. P., & Lim, K. L. (2021). Parkin dysfunction and parkinson's disease. Frontiers in Aging Neuroscience, 13, 674345.

[149] Zhang, P., Xie, M. J., Ruan, X. L., Yuan, S. F., Chen, N. H., & Dai, J. (2019).

[150] PINK1/parkin-mediated mitophagy in Parkinson's disease: Molecular mechanisms and new therapeutic perspectives. CNS Neuroscience & Therapeutics, 25(12), 1232-1241.

[151] Zhou, C., Huang, Y., & Przedborski, S. (2022). Mitochondrial dysfunction in Parkinson's disease. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1868(1), 166376.

[152] Zhu, J., Hu, Z., Han, X., Wang, D., Jiang, Q., Ding, J., ... & Sun, J. (2020). Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of β-arrestin2 and NLRP3. Cell Death & Differentiation, 27(4), 1442-1459.

[153] Zhu, K., van Hilten, J. J., & Marinus, J. (2016). Associated and predictive factors of depressive symptoms in patients with Parkinson's disease. Journal of Neurology, 263(6), 1215-1225.